A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.
A. Jo Chien(University of California, San Francisco), Andrei Goga(University of California, San Francisco), Mehrdad Matloubian(University of California, San Francisco), Siti Rahmaputri(University of California, San Francisco), Julia Rohrberg, Melanie Majure(University of California, San Francisco), Amelia S. Gliwa(University of California, San Francisco), H Dittrich(University of California, San Francisco), John W. Park(University of California, San Francisco), Tasha Lea(University of California, San Francisco), Pamela N. Münster(University of California, San Francisco), Hope S. Rugo(City of Hope), Michelle Melisko(University of California, San Francisco), Gregor Krings(Cleveland Clinic), Mark M. Moasser(University of California, San Francisco)
Cited by 19
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k